Earnings call transcript: Radius Care’s FY 2026 robust growth and stock rise

Radius Residential Care reported a strong FY2026, with revenue up 14% to above NZD 200 million for the first time, net profit before tax up 37%, and EBITDA per care bed rising 3.2% to NZD 31,100. Occupancy improved to 95%, leverage fell to 2.5x from 2.9x, and the final dividend was increased 50% to NZD 0.012 per share. Shares rose 3.9% after the announcement, while management guided to continued FY2027 growth supported by Karori, Applefields, and other expansion projects.

Analysis

The market is rewarding Radius for something broader than an earnings beat: it is proving the model can compound cash while still funding growth. The key second-order readthrough is that occupancy at this level changes the economics of the whole platform — once beds are dense enough, incremental admissions flow disproportionately to cash, which makes any future funding noise or wage inflation less important than the operating leverage embedded in the portfolio.

The more interesting signal is capital allocation. Management is effectively saying it can self-fund a multi-year expansion program without leaning hard on equity, which should pull forward a re-rating versus smaller aged-care peers that still need external capital for every new bed. The mix shift toward higher-acuity residents also matters because it raises switching costs and lowers price elasticity; in practice, that means competitors with more commoditized rest-home exposure are likely to feel margin pressure even if sector demand stays firm.

The main risk is not demand — it is execution on simultaneous build-out and acquisition integration. Over the next 6-18 months, the market will test whether management can open new sites, absorb Karori, and preserve staffing quality without giving back occupancy or incurring cost creep. The contrarian concern is that the stock may already be pricing in flawless compounding; if FY2027 guidance is merely 'good' rather than 'great,' the re-rate could stall even as fundamentals remain healthy.

Key Decisions for Investors

• Long RAD on pullbacks over the next 2-4 weeks: the setup favors a multi-quarter re-rating if management proves self-funded growth; target 10-15% upside with a 5-7% stop if occupancy or leverage trends slip.
• Pair trade: long RAD / short a lower-acuity residential-care peer with weaker occupancy or higher leverage, holding 3-6 months. The spread should widen if funding and staffing remain stable because RAD’s operating leverage is materially better.
• Buy RAD only on days when the market sells healthcare risk broadly: short-term macro weakness can create entry points, but this is a company-specific compounding story rather than a rate-sensitive one.
• For option-oriented accounts, consider RAD call spreads expiring 3-6 months out to capture the re-rating from Karori integration and early FY2027 momentum while capping downside if execution disappoints.
• Trim/add rule: take profits on strength if the stock moves ahead of FY2027 guidance by more than one turn of expected EBITDA leverage, because the next catalyst is operational delivery, not just sentiment.